Microparticle Fractionation Using Ligand Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack efficient tools for enriching and identifying lipid microparticles in bodily fluids, which are potential diagnostic and prognostic markers, due to their heterogeneity and unknown origin, limiting their predictive and therapeutic applications.
Innovation Solution
A method involving size exclusion chromatography and affinity chromatography using Cholera Toxin B and Annexin V to isolate and stratify CD9+ microparticles in plasma, creating distinct subfractions based on GM1 ganglioside and phosphatidylserine binding, allowing for the assessment of physiological or pathological states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If microparticles are isolated from bodily fluids using conventional methods, then microparticles can be obtained for analysis, but the microparticles remain heterogeneous and their identity and origin remain unknown
Solution Approach 1:
The patent divides microparticles into distinct subfractions based on their binding properties to specific ligands (annexin V for phosphatidylserine-containing microparticles and CTB for GM1 ganglioside-containing microparticles). This segmentation allows heterogeneous microparticle populations to be separated into homogeneous subfractions, enabling precise identification and characterization of each subfraction's origin and function.
Solution Approach 2:
The patent introduces specific ligands (annexin V and CTB) as intermediaries that selectively bind to different microparticle subpopulations. These ligands act as mediators to differentiate between microparticles based on their surface composition, allowing researchers to identify and characterize microparticles that would otherwise remain indistinguishable in a heterogeneous mixture.
2Device complexity
If microparticle subfractions are not differentiated, then the analysis process remains simple, but diagnostic and prognostic potential is limited due to heterogeneity
Solution Approach 1:
By segmenting microparticles into distinct subfractions based on their ligand-binding properties, the patent creates well-defined populations that can be reliably analyzed. This segmentation transforms a complex heterogeneous sample into manageable, characterized subfractions, thereby improving diagnostic reliability without requiring overly complex analysis procedures.
Solution Approach 2:
The patent changes the binding parameters of microparticles by introducing specific ligands (annexin V and CTB) that interact with different surface components. This parameter change allows for the differentiation of microparticle subpopulations based on their chemical composition, enhancing diagnostic potential while maintaining analytical simplicity.
3Loss of time
If microparticles are analyzed without fractionation, then processing time is reduced, but predictive and therapeutic applications are limited due to unknown origin
Solution Approach 1:
The patent performs preliminary fractionation of microparticles into distinct subfractions before analysis using simple, rapid methods. This preliminary action organizes the heterogeneous sample into characterized groups, enabling quick identification of microparticle origin and function without requiring time-consuming subsequent analysis, thus preserving both speed and information.
Solution Approach 2:
By using ligand intermediaries (annexin V and CTB) to fractionate microparticles, the patent rapidly obtains information about microparticle origin and composition. These intermediaries provide quick, reliable differentiation of microparticle subpopulations, reducing processing time while preventing loss of critical information about microparticle identity and source.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the rapid isolation and characterization of microparticle subpopulations, enhancing the diagnostic, prognostic, and therapeutic potential of lipid microparticle-based biomarkers by differentiating protein distributions in healthy and diseased states.
Implementation Method 1
The microparticle-containing fractions were isolated by size exclusion chromatography
Implementation Method 2
affinity chromatography using Cholera Toxin B and Annexin V to isolate and stratify CD9+ microparticles
Implementation Method 3
creating distinct subfractions based on GM1 ganglioside and phosphatidylserine binding
Implementation Method 4
affinity chromatography using Cholera Toxin B and Annexin V to isolate and stratify CD9+ microparticles
Implementation Method 5
creating distinct subfractions based on GM1 ganglioside and phosphatidylserine binding
Data Source
AI summary
We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phos—photidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.